+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rapid Diagnostics Market - Global Forecast 2026-2032- Product Image
Rapid Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Rapid Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012257
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Rapid Diagnostics Market is projected to reach USD 37.38 Billion in 2026. It is expected to continue growing at a CAGR of 8.40%, reaching USD 60.94 Billion by 2032.

Rapid diagnostics are reshaping how health systems detect, triage, and manage infectious diseases, chronic conditions, and urgent-care decisions at the point of need. The market spans lateral flow assays, molecular point-of-care testing, immunoassays, rapid antigen tests, glucose and cardiac marker testing, pregnancy and fertility testing, and increasingly connected diagnostic platforms used in hospitals, retail clinics, pharmacies, laboratories, workplaces, community programs, and home-care settings.

Demand is supported by verified public-health priorities: the World Health Organization emphasizes faster testing for tuberculosis, HIV, malaria, hepatitis, influenza, COVID-19, sexually transmitted infections, and antimicrobial resistance, while the U.S. CDC and other national agencies continue to promote timely diagnosis as essential to outbreak control, appropriate therapy, and surveillance. The strongest opportunities in rapid diagnostics are emerging where point-of-care testing shortens time to treatment, reduces unnecessary antimicrobial use, expands access outside centralized laboratories, and improves digital reporting for public-health response.

Transformative Shifts in the Rapid Diagnostics Landscape

The rapid diagnostics landscape is moving from single-use, visually read tests toward connected, multiplexed, and data-enabled testing models. COVID-19 normalized at-home and point-of-care testing, accelerated regulatory familiarity with emergency-use pathways, and expanded consumer expectations for fast, convenient results. At the same time, the European Union In Vitro Diagnostic Regulation, evolving U.S. FDA oversight, and stronger quality requirements across major health systems are raising the bar for clinical evidence, manufacturing controls, labeling, usability, and post-market performance monitoring.

Another transformative shift is the convergence of decentralized care and laboratory-grade performance. Molecular point-of-care systems, digital readers, cloud connectivity, and sample-to-answer platforms are enabling faster decisions in emergency departments, primary care, pharmacies, urgent care centers, and remote settings. Procurement is increasingly influenced by total cost of care, interoperability, reimbursement clarity, supply-chain resilience, biosafety, and the ability to support public-health reporting while maintaining clinical accuracy across diverse patient populations.

Cumulative Impact of Artificial Intelligence on Rapid Diagnostics

Artificial intelligence is becoming a cumulative force across the rapid diagnostics value chain rather than a stand-alone feature. AI supports assay design, biomarker discovery, image-based interpretation, signal enhancement for low-concentration analytes, automated quality control, and workflow optimization. In settings such as digital microscopy, respiratory testing, sepsis risk stratification, antimicrobial stewardship, and connected home diagnostics, AI can help clinicians interpret rapid test results in clinical context and prioritize follow-up testing.

The measurable value of AI in rapid diagnostics depends on validated datasets, transparent performance metrics, cybersecurity, privacy protection, and regulatory-grade clinical evidence. Industry leaders are focusing on human-in-the-loop designs, bias evaluation across populations, device traceability, and integration with electronic health records. The highest-impact use cases will be those that improve sensitivity, reduce invalid tests, accelerate triage, detect operational quality issues, and convert rapid diagnostic results into actionable care pathways without increasing clinician burden.

Key Regional Insights Across Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Asia-Pacific is one of the most dynamic rapid diagnostics regions because of large populations, high infectious-disease testing needs, expanding private healthcare, and government investment in domestic diagnostics capacity. China, India, Japan, South Korea, Australia, and ASEAN markets show rising demand for molecular point-of-care systems, rapid respiratory panels, women’s health testing, diabetes monitoring, and chronic disease screening, supported by broader digital health adoption and growing laboratory networks.

North America remains a major innovation and commercialization hub, supported by advanced reimbursement structures, strong hospital networks, pharmacy-based testing, CLIA-waived testing pathways in the United States, and FDA-cleared platforms. Europe is shaped by the EU IVDR, which is increasing evidence requirements while supporting higher confidence in test performance, clinical documentation, and post-market surveillance. Latin America is gaining traction through decentralized testing for dengue, HIV, tuberculosis, sexually transmitted infections, and respiratory infections, although reimbursement, procurement capacity, and last-mile distribution remain uneven. The Middle East is investing in healthcare modernization, national screening programs, and digital health infrastructure, while Africa’s rapid diagnostics adoption is strongly linked to malaria, HIV, tuberculosis, maternal health, outbreak preparedness, and donor-supported access initiatives coordinated with national health ministries.

Key Group Insights Covering ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are expanding rapid diagnostics through public-health programs, local distribution partnerships, and private-sector growth in Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines. The region’s priorities include dengue, tuberculosis, respiratory infections, maternal health, antimicrobial resistance monitoring, and affordable point-of-care testing in decentralized settings where laboratory access can vary between urban and rural populations.

The GCC is accelerating adoption through hospital modernization, national screening initiatives, medical tourism, and digital health infrastructure in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. The European Union is defined by IVDR compliance, cross-border quality expectations, and demand for clinically validated diagnostics that support antimicrobial stewardship and patient safety. BRICS countries represent high-volume opportunities in infectious disease, chronic disease, and domestic manufacturing, with policy emphasis on healthcare access and local production capacity. G7 markets lead in premium platforms, reimbursement evolution, companion testing integration, and clinical workflow adoption, while NATO countries emphasize preparedness, biosecurity, and resilient diagnostic supply chains for civilian and defense-related health readiness.

Key Country Insights for Rapid Diagnostics Adoption

The United States leads in rapid diagnostics innovation through FDA-cleared platforms, retail-clinic expansion, hospital point-of-care programs, CLIA-waived testing, and strong investment in molecular and digital testing. Canada emphasizes quality-assured diagnostics across provincial health systems, while Mexico and Brazil show growing demand for infectious-disease, women’s health, dengue, respiratory illness, and chronic-care testing in mixed public-private systems that depend on distribution reach and procurement efficiency.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are prioritizing validated rapid testing that supports antimicrobial stewardship, respiratory disease management, emergency care, and decentralized healthcare under tighter regulatory expectations. Germany and France benefit from strong laboratory and hospital infrastructure, the United Kingdom emphasizes diagnostic access and care pathway efficiency, and Italy and Spain continue to expand rapid testing for respiratory, cardiovascular, and infectious disease use cases. Russia maintains demand for infectious-disease and hospital diagnostics despite trade, procurement, and supply-chain constraints.

China and India are major rapid diagnostics engines because of scale, domestic manufacturing, high testing volumes, and public-health needs spanning respiratory infections, tuberculosis, hepatitis, diabetes, and maternal health. Japan, South Korea, and Australia are advanced markets with strong quality standards, aging populations, established reimbursement structures, and adoption of connected diagnostic tools. Across these countries, rapid diagnostics adoption depends on clinical accuracy, affordability, reimbursement, distribution reliability, regulatory compliance, local service support, and integration with care pathways.

Actionable Recommendations for Rapid Diagnostics Industry Leaders

Industry leaders should prioritize clinically differentiated rapid diagnostics that prove measurable value in faster treatment, reduced hospital burden, antimicrobial stewardship, and improved access. Product portfolios should balance high-volume lateral flow tests with molecular point-of-care platforms, multiplex respiratory panels, cardiac markers, women’s health diagnostics, diabetes monitoring, and digital readers that support traceability, quality control, and reporting.

Organizations should strengthen regulatory readiness for FDA, EU IVDR, and other national requirements by investing in real-world evidence, quality systems, usability studies, analytical validation, clinical validation, and post-market surveillance. Partnerships with pharmacies, primary-care networks, public-health agencies, laboratories, community programs, and telehealth providers can extend reach. Supply-chain localization, AI governance, cybersecurity, reimbursement evidence, and health-equity considerations should be treated as strategic priorities rather than operational afterthoughts.

Research Methodology for Rapid Diagnostics Analysis

This executive summary is based on secondary research and analytical triangulation from verified public-health, regulatory, clinical, and industry sources. Core references include guidance and datasets from the World Health Organization, U.S. CDC, U.S. FDA, European Commission, national health ministries, peer-reviewed journals, and recognized standards bodies. The analysis considers disease burden, regulatory policy, technology adoption, procurement patterns, reimbursement trends, digital health readiness, and healthcare infrastructure maturity.

Insights are synthesized using a top-down and bottom-up research approach that compares macro-level health priorities with product-level adoption indicators. Regional and country assessments consider demographic trends, infectious-disease prevalence, chronic disease needs, healthcare access, local manufacturing capacity, regulatory requirements, and decentralized care adoption. All claims are framed to avoid unsupported market estimates and focus on evidence-backed drivers, restraints, and opportunities in rapid diagnostics.

Conclusion: The Future of Rapid Diagnostics

Rapid diagnostics are becoming a strategic pillar of modern healthcare because they connect speed, access, and actionable clinical decision-making. The category is no longer defined only by test turnaround time; it is increasingly defined by accuracy, connectivity, usability, regulatory evidence, affordability, and the ability to improve patient outcomes across decentralized care settings.

The next phase of development will be led by validated molecular point-of-care systems, AI-enabled interpretation, multiplex testing, home diagnostics, and digitally connected platforms that support surveillance and care coordination. Organizations that combine scientific credibility, scalable manufacturing, regulatory excellence, resilient supply chains, and strong regional partnerships will be best positioned to advance the rapid diagnostics landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Rapid Diagnostics Market, by Product Type
7.1. Introduction
7.2. Instruments
7.2.1. Benchtop
7.2.2. Portable
7.3. Reagents & Consumables
7.4. Test Kits
8. Rapid Diagnostics Market, by Technology
8.1. Introduction
8.2. Immunoassay
8.3. Lateral Flow Assay
8.3.1. Competitive
8.3.2. Sandwich
8.4. Molecular Diagnostics
8.4.1. Isothermal Amplification
8.4.2. Pcr
9. Rapid Diagnostics Market, by Sample Type
9.1. Introduction
9.2. Blood
9.2.1. Whole Blood
9.2.2. Serum
9.2.3. Plasma
9.3. Urine
9.4. Saliva
9.5. Swab
9.5.1. Nasal
9.5.2. Nasopharyngeal
9.5.3. Throat
9.6. Stool
10. Rapid Diagnostics Market, by Application
10.1. Introduction
10.2. Cardiac Markers
10.2.1. Creatine Kinase Mb
10.2.2. Myoglobin
10.2.3. Troponin
10.3. Diabetes
10.3.1. Type 1 Diabetes
10.3.2. Type 2 Diabetes
10.4. Infectious Diseases
10.4.1. Bacterial Infections
10.4.2. Parasitic Infections
10.4.3. Viral Infections
10.5. Oncology
11. Rapid Diagnostics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
11.5. Laboratories
12. Rapid Diagnostics Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Rapid Diagnostics Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Rapid Diagnostics Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Abingdon Health plc
16.3. Access Bio, Inc.
16.4. Becton, Dickinson and Company
16.5. Bio-Rad Laboratories, Inc.
16.6. BioGnost d.o.o.
16.7. bioMérieux SA
16.8. Chembio Diagnostics, Inc.
16.9. CTK Biotech, Inc.
16.10. Danaher Corporation
16.11. EKF Diagnostics Holdings plc
16.12. F. Hoffmann-La Roche Ltd.
16.13. GenBody Inc.
16.14. Guangzhou Wondfo Biotech Co., Ltd.
16.15. Hangzhou AllTest Biotech Co., Ltd.
16.16. Hardy Diagnostics
16.17. InBios International, Inc.
16.18. Lepu Medical Technology (Beijing) Co., Ltd.
16.19. Meridian Bioscience, Inc.
16.20. OraSure Technologies, Inc.
16.21. QuidelOrtho Corporation
16.22. SD Biosensor, Inc.
16.23. Sekisui Diagnostics, LLC
16.24. Siemens Healthineers AG
16.25. SureScreen Diagnostics Ltd
16.26. Thermo Fisher Scientific Inc.
16.27. Trinity Biotech plc
List of Figures
FIGURE 1. GLOBAL RAPID DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RAPID DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RAPID DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RAPID DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RAPID DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BENCHTOP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BENCHTOP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BENCHTOP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PORTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PORTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PORTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TEST KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TEST KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TEST KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL COMPETITIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL COMPETITIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL COMPETITIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SANDWICH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SANDWICH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SANDWICH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SWAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SWAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SWAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL NASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL NASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NASOPHARYNGEAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NASOPHARYNGEAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NASOPHARYNGEAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL THROAT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL THROAT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL THROAT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL STOOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL STOOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL STOOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CARDIAC MARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CARDIAC MARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CARDIAC MARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CREATINE KINASE MB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CREATINE KINASE MB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CREATINE KINASE MB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL MYOGLOBIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL MYOGLOBIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL MYOGLOBIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TROPONIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TROPONIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL TROPONIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 142. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 143. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 144. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 145. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 146. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 147. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 148. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 149. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 151. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 152. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 153. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 183. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 184. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 185. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 186. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 187. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 188. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 189. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 190. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 191. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 193. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 194. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 195. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. NATO RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. NATO RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 213. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 214. NATO RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 215. NATO RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 216. NATO RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 217. NATO RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 218. NATO RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 219. NATO RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 220. NATO RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 221. NATO RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 222. NATO RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 223. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 224. NATO RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. G7 RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. G7 RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 227. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 228. G7 RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 229. G7 RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 230. G7 RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 231. G7 RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 232. G7 RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 233. G7 RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 234. G7 RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 235. G7 RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 236. G7 RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 237. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 238. G7 RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 240. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 241. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 242. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 243. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 244. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 245. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 246. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 247. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 248. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 249. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 250. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 251. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 252. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 268. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 269. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 270. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 271. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 272. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 273. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 274. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 275. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 276. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 278. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 279. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 280. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. GCC RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 282. GCC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 283. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 284. GCC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 285. GCC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 286. GCC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 287. GCC RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 288. GCC RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 289. GCC RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 290. GCC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 291. GCC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 292. GCC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 293. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 294. GCC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 296. CHINA RAPID DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 298. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 299. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 300. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 301. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 302. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 303. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 304. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 305. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 306. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 307. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 308. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 309. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 312. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 313. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 314. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 315. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. JAPAN RAPID DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 326. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 327. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 328. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 329. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 330. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 331. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 332. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 333. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 334. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 335. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 336. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 337. JAPAN RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 338. INDIA RAPID DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 339. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 340. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 341. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 342. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 343. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 344. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 345. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 346. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 347. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 348. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 349. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 350. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 351. INDIA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 352. GERMANY RAPID DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 353. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 354. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 355. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 356. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 357. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 358. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 359. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 360. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 361. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 362. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 363. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 364. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 365. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 366. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 367. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 368. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 369. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 370. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2017-2032 (USD MILLION)
TABLE 371. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 372. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 373. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 374. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 375. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 376. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2017-2032 (USD MILLION)
TABLE 377. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 378. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 379. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE,

Companies Mentioned

  • Abbott Laboratories
  • Abingdon Health plc
  • Access Bio, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioGnost d.o.o.
  • bioMérieux SA
  • Chembio Diagnostics, Inc.
  • CTK Biotech, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd.
  • GenBody Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Hangzhou AllTest Biotech Co., Ltd.
  • Hardy Diagnostics
  • InBios International, Inc.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Meridian Bioscience, Inc.
  • OraSure Technologies, Inc.
  • QuidelOrtho Corporation
  • SD Biosensor, Inc.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • SureScreen Diagnostics Ltd
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 37.38 Billion
Forecasted Market Value ( USD ) by 2032 $ 60.94 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Respiratory Infection Diagnostics Market - Global Forecast 2026-2032 - Product Image

Respiratory Infection Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
RSV Diagnostics Market - Global Forecast 2026-2032 - Product Image

RSV Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Artificial Intelligence (AI) in Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Artificial Intelligence (AI) in Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Artificial Intelligence (AI) in Medical Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Artificial Intelligence (AI) in Medical Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Paper Diagnostics - Global Strategic Business Report - Product Image

Paper Diagnostics - Global Strategic Business Report

  • Report
  • 275 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.